Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05848258 · ClinicalTrials.gov registry record · Phase 2

An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

A Phase 2 study of Rheumatoid Arthritis, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 2
Development phase
380
Enrollment target
20
Study locations

NCT05848258 is a Phase 2 study of Rheumatoid Arthritis that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 380 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05848258, a Phase 2 study of Rheumatoid Arthritis, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 2
Development phase
380 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG Placebo
  • DRUG LY3871801

Study Locations (20)

Other

  • CIPREC - Buenos Aires
  • Mautalen Salud e Investigación - Buenos Aires
  • CENUDIAB - Buenos Aires
  • Medicina Reumatológica - San Fernando
  • Instituto de Alta Complejidad San Isidro - San Isidro
  • Medical Plus - Uherské Hradiště
  • CHD Vendee - La Roche-sur-Yon
  • CHU Montpellier Lapeyronie Hospital - Montpellier

Florida

  • Integrity Clinical Research - Doral
  • Advanced Clinical Research of Orlando - Ocoee - Ocoee
  • Encore Medical Research - Weston - Weston
  • Conquest Research - Winter Park

New York

  • Joseph S. and Diane H. Steinberg Ambulatory Care Center - Brooklyn
  • Icahn School of Medicine at Mount Sinai - New York

California

  • Newport Huntington Medical Group - Huntington Beach

Illinois

  • Willow Rheumatology and Wellness PLLC - Willowbrook

Louisiana

  • Accurate Clinical Research, Inc - Lake Charles

North Carolina

  • Accellacare - Salisbury - Salisbury

Texas

  • Accurate Clinical Research, Inc - Houston

Trial Details

FieldValue
Enrollment Target 380 participants
Start Date 2023-05-23
Est. Completion 2026-07
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05848258

The ClinicalTrials.gov registry entry for NCT05848258 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (92% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05848258 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT05848258 about?

NCT05848258 is a clinical study titled "An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis". The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).

What is the current status of trial NCT05848258?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 380 participants. The study started on 2023-05-23. Estimated completion is 2026-07.

What conditions does trial NCT05848258 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT05848258?

The interventions under investigation include: Placebo (DRUG), LY3871801 (DRUG).

Who is sponsoring clinical trial NCT05848258?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05848258 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Louisiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.